Contact us on +44 (0)1270 270010 | info@boydconsultants.com

Guidance – licensing pathway: Innovative licensing and access pathway

Guidance – licensing pathway: Innovative licensing and access pathway
April 1, 2021 SueCarr

The MHRA is introducing a new innovative licensing and access pathway (ILAP) to accelerate the time to market for ATMPs, new biological or chemical entities, new indications, repurposed medicines and medicines for rare diseases or special populations.

The ILAP is open to both commercial and non-commercial developers of medicines (UK or global) and provides applicants with opportunities for enhanced regulatory and other stakeholder input to support all stages of the design, development and approvals process.